40 versus an already lowered loss estimate of .32. The combination of the poor sales report and increased expenses sent VVUS stock plummeting more than 21% Tuesday before closing down 3.13 at 11.82 a share. …
On Jan 3, we issued an updated report on VIVUS, Inc. (VVUS - Free Report) . VIVUS’ three-month share price movement shows that the stock has significantly outperformed the Zacks classified Medical-Biomed/Genetics …
ZACKS1mon
VIVUS, Inc. (NASDAQ:VVUS) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Tuesday. According to Zacks, “Shares of VIVUS outperformed that of the …
Tina provides the U.S. as well as global markets commentary that cover the stock, commodity, and currency markets. She covers latest activity, events and trends, from economic reports and financial indicators relating …
At the same time, VVUS closed at $5.78 with an only 2.48% increase. The comparison between the stock characteristics of both companies shows that they have a lot of similarities. The market value of ARNA is …
Stock market analysts and brokers have recently amended their target prices on shares of VIVUS, Inc. (NASDAQ:VVUS). According to the latest research reports released, 0 analysts have issued a rating of “buy”, …
Furthermore, let’s examine the newest info surrounding VIVUS, Inc. (NASDAQ:VVUS). At the end of the second quarter, a total of 26 of the hedge funds we track were bullish in this stock, a change of 24% from the first …
Hedge fund
Stock-Callers.com today has issued research reports on four Biotechnology equities, which are Emergent …
Emergent Biosolutions, Inc.
Vivus’s (NASDAQ: VVUS) weight loss pill Qnexa, which awaits clearance from U.S Regulators, is thought to cause psychiatric and cardiovascular side effects and hasn’t been sufficiently tested in pregnant women. …